home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

294 rows where filing_period = "second_quarter", filing_year = 2024 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 294 ✖

filing_year 1

  • 2024 · 294 ✖

filing_period 1

  • second_quarter · 294 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
3183532 PORT SIDE STRATEGIES, LLC 163f69aa-478a-4b01-a55b-dcf0ce95f3cc 2T PORT SIDE STRATEGIES, LLC 401105394 NEW VENTURE FUND 2024 second_quarter PHA H.R.4895 - Lowering Drug Costs for American Families Act - in support. Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 1 2024-05-16T21:31:12-04:00
3183995 BLUESTONE STRATEGIES, LLC 67c7eca6-a703-42e3-98f0-bdcedc373954 2T BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2024 second_quarter PHA Pharmacy contracting issues related to drug pricing and pharmacy networks. HR 5378, The Lower Costs More Transparency Act S. 127, The PBM Transparency Act - Issues related to the FTC study of Pharmacy Benefit Managers. S. 1339, The Pharmacy Benefit Manager Reform Act - Issues related to the banning of spread pricing and rebate pass throughs S. 1967, The Patients Before Middlemen Act - Issues related to delinking and limiting PBMS ability to manage pharmacy benefits in Medicare. HOUSE OF REPRESENTATIVES,SENATE 40000   0 1 2024-06-04T14:23:35-04:00
3184564 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) b802b3d8-9f3a-4bb5-afb8-188872da3d83 Q2 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2024 second_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-06-28T09:00:35-04:00
3184595 4C COMMUNICATIONS, INC. 41524d12-e254-4b70-8c57-b7395a237cec 2T 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2024 second_quarter PHA H.R. 7050, Substance Use Disorder Workforce Act H.R. 7312, Electronic Prescribing for Controlled Substances 2.0 Act S. 2666, Electronic Prescribing for Controlled Substances Act HOUSE OF REPRESENTATIVES,SENATE     0 1 2024-06-28T14:13:37-04:00
3184707 PENN AVENUE PARTNERS 10b4230a-7780-45a3-a213-b648de6e36a7 Q2 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2024 second_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2024-07-01T05:19:49-04:00
3184714 PENN AVENUE PARTNERS 10dd0ad2-9cf1-4550-a762-9871f3a675e6 Q2 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2024 second_quarter PHA Regulatory and legislative issues impacting Alkermes. Appropriations. HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 50000   0 0 2024-07-01T05:24:45-04:00
3184886 AMERICAN COLLEGE OF CLINICAL PHARMACY 67e8a608-5a36-4b84-abd7-bb73dee5d2c4 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2024 second_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2024-07-01T10:54:57-04:00
3185074 REPUBLIC CONSULTING, LLC d155dca3-4598-46a2-8611-2a3831d1dea9 Q2 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2024 second_quarter PHA Monitor Health Data Policy. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-01T14:44:07-04:00
3185159 E3 STRATEGIC CONSULTING GROUP 438d4de9-ed81-4804-8a09-6f8a4ff0cb99 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2024 second_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023; H.R.830 - HELP Copays Act; S. 1542 - Delinking Revenue from Unfair Gouging Act (a/k/a The DRUG Act"); HR 4895 - H.R. 4895: Lowering Drug Costs for American Families Act; H.R. 2880: Protecting Patients Against PBM Abuses Act; HR 6283 - The Drug Act; HR 5378 - Lower Costs, More Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-01T16:18:13-04:00
3185177 FROST BROWN TODD LLC c92e1559-ea3d-4943-8276-69ec7c00573d Q2 FROST BROWN TODD LLC 283572 DISPOSERX 2024 second_quarter PHA Support Act, SIPPI Act Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-01T16:39:58-04:00
3185658 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 596b20c2-f147-4dc0-a8cb-fa185ca009fc Q2 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2024 second_quarter PHA 340B, Hospital at Home Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   34865 0 0 2024-07-03T08:15:00-04:00
3185923 DAVE KOLBE CONSULTING 0bc1b8ce-c413-4098-b2da-ae3e2a507609 Q2 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2024 second_quarter PHA H.R. 6283 (Delinking Revenue from Unfair Gouging Act) - Calling attention to the immediate need to enact pharmacy benefit manager (PBM) reforms to reduce Americans' prescription drug costs and protect pharmacy business across the country. Request to co-sponsor the Act. H.R. 2880 (Protecting Patients Against PBM Abuses Act) - Request to co-sponsor the Act. Senate Judiciary Committee - Affordable Medication and Competition in the Drug Market - PBM reform and IP Protections - Asking for support for pharmacy benefit manager (PBM) reform and IP Protections. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-03T17:00:20-04:00
3186031 WAKEFERN FOOD CORP. 1acc68e7-41b5-4ccb-b9c7-8f3cf312f009 Q2 WAKEFERN FOOD CORP. 400588798 WAKEFERN FOOD CORP. 2024 second_quarter PHA Comprehensive pharmacy benefit manager (PBM)/DIR fee reform H.R. 5378 - "Lower Costs, More Transparency Act" S. 3430 - "Better Mental Health Care, Lower-Cost Drugs, and Extenders Act" S. 2973 - "Modernizing and Ensuring PBM Accountability Act" Legislative measures add more transparency HOUSE OF REPRESENTATIVES,SENATE     0 0 2024-07-05T10:52:01-04:00
3186237 RED+BLUE STRATEGIES a27ff12b-c229-4ffb-b10a-5516920242ac Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2024 second_quarter PHA H.R. 7623 - Telehealth Modernization Act of 2024 - Support for the underlying telemedicine extension, yet concern for the commercial delinking offset included in the legislation. H.R. 4366 - Consolidated Appropriations Act of FY 2024 - Issues related to health care policy provisions included in the bill writ large. H.R. 2882 - Further Consolidated Appropriations Act of FY 2024 - Issues related to funding of the Department of Health and Human Services and agencies governing programs dedicated to the coverage of prescription medications. S. 2973 - Modernizing and Ensuring PBM Accountability Act - Issues related to the important role PBMs play in keeping drug prices low for public and private employers and their employees. S. 3430 Better Mental Health Care, Lower Cost Prescription Drugs and Extenders Act of 2023- Issues related to pharmacy benefit managers and their role in keeping drug prices lower for patients. H.R. 3561 - The PATIENT Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. H.R. 5378 - Lower Costs, More Transparency Act of 2023 - Issues related to PBMs and their ability to successfully support the national goal of bringing down the cost of prescription medications in the public and private sectors. S. 1967 - The PBM Act - Issues related to delinking and limiting current tools used by PBMS to manage pharmacy benefits in Medicare. S. 1339 - The Pharmacy Benefit Manager Reform Act - Issues focused on limiting spread pricing and requiring rebate pass through and other tools used to control the price of prescription medications. S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. … Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE 70000   0 0 2024-07-06T09:12:24-04:00
3186429 MASON STREET CONSULTING, LLC 955f240a-8b40-4fb6-93f4-35ec7ef199aa Q2 MASON STREET CONSULTING, LLC 401105150 CAPITAL RX INC. 2024 second_quarter PHA PBM Reform. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-07T08:58:05-04:00
3186503 NATIONAL ASSOCIATION OF CHAIN DRUG STORES d765aa46-9c82-4922-8581-f4b0faf733d8 Q2 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2024 second_quarter PHA Lower healthcare costs and bring transparency to pharmacy benefit managers (PBMs) through meaningful PBM reforms. H.R. 1613 Drug Price Transparency in Medicaid Act H.R. 1770 Equitable Community Access to Pharmacist Services Act H.R. 2534 Protect 340B Act of 2023 H.R. 2816 The PBM Sunshine and Accountability Act H.R. 2880 Protecting Patients Against PBM Abuses Act H.R. 2882 Fiscal 2024 Further Consolidated Appropriations Act (3-22 package) H.R. 3561 The Patient Act H.R. 4366 Consolidated Appropriations Act, 2024 (3-8 package H.R. 5378 Lower Costs, More Transparency Act H.R. 5385 The Medicare PBM Accountability H.R. 5393 To amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes. H.R. 5400 TheNeighborhood Options for Patients Buying Medicines (NO PBMs) Act H.R. 7623 Telehealth Modernization Act of 2024 H.R. 7635 The 340B Patients Act of 2024 H.R. 8574 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act S. 1038Drug Price Transparency in Medicaid Act S. 113Prescription Pricing for the People Act S. 127Pharmacy Benefit Manager Transparency Act S. 1339Pharmacy Benefit Manager Reform Act S. 1491Pharmacy and Medically Underserved Areas Enhancement Act S. 2052Protect Patient Access to Pharmacies Act S. 2436TheNeighborhood Options for Patients Buying Medicines (NO PBMs) Act S. 2477Equitable Community Access to Pharmacist Services Act S. 2666ECAPS 2.0 Act S. 2973Modernizing and Ensuring PBM Accountability Act (MEPA) S. 3393The SUPPORT Act S. 3430Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023 (Better Act) HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,White House Office   1800000 0 0 2024-07-08T08:35:53-04:00
3186869 DENTONS US LLP dc734910-e23d-4f7f-9f62-22ebc8b021db Q2 DENTONS US LLP 36105 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA 2024 second_quarter PHA Federal issues impacting workforce and innovation in the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-08T16:28:01-04:00
3186986 THE MAJORITY GROUP, LLC 3b91469e-53cc-48af-82f6-526569725807 Q2 THE MAJORITY GROUP, LLC 400713141 SHARX, LLC 2024 second_quarter PHA Advocate on behalf of SHARx with Congress and relevant agencies on solutions involving the high costs of prescription medications. HOUSE OF REPRESENTATIVES,SENATE 65000   0 0 2024-07-09T09:23:32-04:00
3187065 MCDERMOTT+ LLC 3799165c-8552-43ed-b5b5-702ef0675195 Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2024 second_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-07-09T11:20:07-04:00
3187284 RAY ANDERSON 4c83a7ca-94f0-4864-9393-444c254f875b Q2 RAY ANDERSON 401105487 340B HEALTH 2024 second_quarter PHA Contract Pharmacy-HR 7635, The 340B PATIENTS Act of 2024 340B Transparency-No legislation yet Contract Pharmacy Protect 340B-340B Patients Act 340B Transparency-Opposition to H.R. 3290 (overly burdensome reporting legislation that distorts the 340B program) HOUSE OF REPRESENTATIVES     0 0 2024-07-09T13:53:05-04:00
3187795 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION ed41b364-9371-4e3a-9f92-be72866b86c5 Q2 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2024 second_quarter PHA Discussed issues related to BIOSECURE Act, drug shortages, pandemic preparedness, advanced manufacturing, onshoring/friendshoring initiatives, and biopharmaceutical supply chains HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2024-07-10T11:16:42-04:00
3188059 MARSHALL & POPP, LLC 6cb41732-f98c-4ac9-948f-699318899057 Q2 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2024 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-10T14:48:35-04:00
3188078 MARSHALL & POPP, LLC 8795b422-2834-492d-9f1e-ff37f74673cf Q2 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2024 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-10T14:56:26-04:00
3188103 MARSHALL & POPP, LLC 0633190e-d2b6-47c5-a1cb-29f3390359a8 Q2 MARSHALL & POPP, LLC 401105121 PFIZER, INC. 2024 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-10T15:02:40-04:00
3188130 MARSHALL & POPP, LLC aeda8ec8-bbb9-4894-a49e-306d7403e3f2 Q2 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2024 second_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act, S.1339 - Pharmacy Benefit Manager Reform Act, H.R. 2679, the PBM Accountability Act, H.R.4822 - Health Care Price Transparency Act, H.R. 5378 - Lower Costs, More Transparency Act. Issues related to the 340B program, including H.R. 3290, to ensure transparency and oversight of the 340B drug discount program. Pandemic All-Hazards Preparedness Act (PAHPA) reauthorization, including S.2333 - Pandemic and All-Hazards Preparedness and Response Act. Issues related to Type 1 diabetes screening. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-10T15:17:31-04:00
3188484 MR. H.R. BERT PENA 35a72f5b-c0ec-4c2e-9ed3-7a103599223e Q2 MR. H.R. BERT PENA 400323519 MARGO RX LLC(DBA RICHARD'S PHARMACY) 2024 second_quarter PHA PBM AND DRUG PRICES Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES     0 0 2024-07-11T10:19:32-04:00
3188759 GOVERNMENT COUNSEL, LLC bb9efb6d-24a4-4e6f-b5e8-8296f08acbc6 Q2 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2024 second_quarter PHA Issues relating to the prevention and mitigation of pharmaceutical shortages. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-11T12:46:29-04:00
3188840 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 6485cf90-debe-4d44-91de-6a0c88b82230 Q2 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2024 second_quarter PHA CCAGW Urges Senate Judiciary Committee to Protect IP rights in Biopharmaceutical Industry CCAGW Submits Testimony to House Energy and Commerce Committee on 340B drug discount program HOUSE OF REPRESENTATIVES,SENATE   100000 0 0 2024-07-11T13:39:30-04:00
3188843 LMH STRATEGIC SOLUTIONS f2ccb890-7e08-46e3-b597-74878432fae9 Q2 LMH STRATEGIC SOLUTIONS 401108183 AVADEL PHARMACEUTICALS, PLC 2024 second_quarter PHA Prescription Drug Competition Issues. H.R.4692/S.574 - Increasing Prescription Drug Competition Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-11T13:40:51-04:00
3188850 LMH STRATEGIC SOLUTIONS e8f8aa8a-b87a-4c5d-8ae3-2d4f8a5ad28c Q2 LMH STRATEGIC SOLUTIONS 401108183 GLAXOSMITHKLINE LLC 2024 second_quarter PHA General healthcare issues impacting GSK. H.R.7085 - BIOSECURE Act. H.R.830 - HELP Copays Act. H.R.5378 - Lower Costs, More Transparency Act. S.1542 - DRUG Act. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-07-11T13:48:04-04:00
3188857 LMH STRATEGIC SOLUTIONS 506232f8-da19-44f6-ba24-b36b6ca4dc65 Q2 LMH STRATEGIC SOLUTIONS 401108183 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 second_quarter PHA Prescription drug payment reform. Drug Pricing and Access. Pharmaceutical Supply Chain. Pharmacy Benefit Managers. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-11T13:51:02-04:00
3189445 FLYNN & ASSOCIATES, INC. 7fe96de9-2251-4fea-a7c8-b5cbfeda9457 Q2 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2024 second_quarter PHA Drug importation Price controls Pharmacy Benefit Manager issues HR 2880 and HR 6283 HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-12T12:21:55-04:00
3189585 TARPLIN, DOWNS & YOUNG, LLC a8ab7cd6-8753-4735-9858-63840af2c544 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2024 second_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 80000   0 0 2024-07-12T13:52:07-04:00
3189611 PUBLIC CITIZEN e0918c5c-b2da-400e-878b-15b8bec85069 Q2 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2024 second_quarter PHA Medicare drug price negotiation eligibility, providing negotiated prices to commercial market and other improvements, Medicare Part D noninterference clause, clinical trial cost transparency, march-in rights and other Bayh-Dole rights, PASTEUR Act, Plain Prescription Prices Act, public pharmaceutical manufacturing, .79 Interagency Patent Coordination and Improvement Act; S.113 Prescription Pricing for the People Act; S.142 Preserve Access to Affordable Generics and Biosimilars Act; S.148 Stop STALLING Act; S.150, S.954 Affordable Insulin Now Act, weight loss drug pricing. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   73300 0 0 2024-07-12T14:06:41-04:00
3190091 FORBES-TATE d111ad3f-d63c-4f32-9f06-94b11635eb83 Q2 FORBES-TATE 400976792 PHRMA 2024 second_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-07-13T01:35:32-04:00
3190278 THORSEN FRENCH ADVOCACY LLC 164aa69d-fb17-43c1-aafa-4a2c107769b7 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2024 second_quarter PHA General issues related to opioid abuse and access to medication assisted treatment. Drug Shortages. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-13T14:29:36-04:00
3190294 THORSEN FRENCH ADVOCACY LLC b8ebcc9a-8fbd-423d-a956-0eb595fc94c7 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2024 second_quarter PHA Issues related to drug pricing. Issues realted to anti-competitive tactics in the pharmaceutical marketplace. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-13T14:43:33-04:00
3190780 FORBES-TATE 85346aa1-3c14-4384-bbf0-643a27df37fe Q2 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2024 second_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Pharmacy Benefit Managers. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-07-14T14:10:39-04:00
3190830 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7d72bd7f-041b-43b3-bc04-d9532b957b1b Q2 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2024 second_quarter PHA Pharmacist provider status Issues related to drug pricing Issues related to access and distribution of pharmaceutical products Issues related to HIV Testing HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-14T14:55:10-04:00
3191272 KOUNTOUPES DENHAM CARR & REID, LLC 86857ac8-8fe3-464d-bd2f-c07dfdc35806 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ABBOTT LABORATORIES 2024 second_quarter PHA Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-15T08:52:29-04:00
3191294 AMERICAN VETERINARY MEDICAL ASSOCIATION bf187fcc-4caf-4b4a-b855-aaa8fb8b98f9 Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2024 second_quarter PHA H.R. 1839/S. 993 Combating Illicit Xylazine Act, all provisions H.R. 4531 Support for Patients and Communities Reauthorization Act, Section 203 S. 3393 SUPPORT for patients and Communities Reauthorization Act, review of language related to xylazine for potential inclusion S. Amendment #1916 to H.R. 3935 FAA Reauthorization Act of 2024, updated Combating Illicit Xylazine Act language Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE   340000 0 0 2024-07-15T09:09:30-04:00
3191352 KOUNTOUPES DENHAM CARR & REID, LLC e9c9684c-7015-4f38-a261-5e1bc7a2f6da Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 AMERICAN KRATOM ASSOCIATION 2024 second_quarter PHA Issues related to Food and Drug Administration regulatory and consumer access. Issues related to H.R. 5905, Federal Kratom Consumer Protection Act, and the Fiscal Year 2025 Agriculture Appropriations bills. HOUSE OF REPRESENTATIVES 50000   0 0 2024-07-15T09:53:53-04:00
3191373 WAXMAN STRATEGIES 65a2d48e-1bfc-4b88-a0ad-b1220a9330ad Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2024 second_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2024-07-15T10:06:50-04:00
3191645 ACADEMY OF MANAGED CARE PHARMACY ee71ce1b-400e-4f21-850f-75e959a6a3f2 Q2 ACADEMY OF MANAGED CARE PHARMACY 48793 ACADEMY OF MANAGED CARE PHARMACY 2024 second_quarter PHA Access to Prescription Digital Therapeutics Act of 2023 (S. 723/H.R. 1458) - To create a benefit category under Medicare and Medicaid allowing for the coverage of prescription digital therapeutics Medicaid VBPs for Patients Act (H.R. 2666) - To codify the existing Medicaid "multiple best price" rule related to value-based purchasing arrangements for drug therapies in Medicaid programs, to expand the use of value-based arrangements to drugs covered under Medicaid administered in an inpatient setting, and to make technical changes to pharmaceutical manufacturer report requirements to CMS related to these changes. Equitable Community Access to Pharmacy Services Act (H.R. 1770) - To make permanent certain emergency authorizations from the COVID-19 public health emergency related to pharmacist-provided care for COVID-19, RSV, and influenza (such as testing and immunization) and to allow reimbursement for these services under Medicare Part B. Also to automatically implement these authorizations for future public health emergencies declared under either the Public Health Service Act or the PREP Act. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   240000 0 0 2024-07-15T11:42:00-04:00
3192278 FOLEY & LARDNER LLP e1a2e14a-4d96-4e01-8acc-5d6a717c8323 Q2 FOLEY & LARDNER LLP 15042 ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY 2024 second_quarter PHA Issues related to 340B; issues related to implementation of the Inflation Reduction Act and the Bipartisan Infrastructure Bill; Issues related to supply chain resilience. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-07-15T14:57:59-04:00
3192340 KOUNTOUPES DENHAM CARR & REID, LLC 0c1d55e1-6c56-454b-abe7-03e7dc4a635d Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2024 second_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-15T15:21:13-04:00
3192361 KOUNTOUPES DENHAM CARR & REID, LLC 088bb738-949f-416c-8089-e3df4bf6a35d Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2024 second_quarter PHA General issues related to Over-The-Counter (OTC) pharmaceutical supply chain. Issues related to Drug Enforcement Administration Pseudoephedrine quotas. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-15T15:33:37-04:00
3192406 KOUNTOUPES DENHAM CARR & REID, LLC 551293eb-1454-4f31-845e-fb140ad9f5e5 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2024 second_quarter PHA Issues related to drug pricing transparency. Issues related to pharmacy benefit managers. Issues related to testing, vaccination and treatment including H.R. 1770 and S. 2477, the Equitable Community Access to Pharmacist Services Act. Issues related to pharmaceutical access and affordability. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-15T15:46:25-04:00
3192767 2359 STRATEGIES 29e25151-6bec-4fe0-b9c4-3c272b8dd755 Q2 2359 STRATEGIES 401106114 TRAVERE THERAPEUTICS 2024 second_quarter PHA Orphan Drug Act HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2024-07-15T17:54:19-04:00
3192913 PORT SIDE STRATEGIES, LLC 49fc9116-f8dc-44da-ad88-4c922749566b Q2 PORT SIDE STRATEGIES, LLC 401105394 CENTER FOR HEALTH AND DEMOCRACY 2024 second_quarter PHA Issues related to out-of-pocket costs. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-15T20:46:20-04:00
3193127 DESIMONE CONSULTING, LLC bc8c0297-1c46-497f-8c3f-95b68194987b Q2 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2024 second_quarter PHA Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform; H.R. 2880, Protecting Patients Against PBM Abuses Act and H.R.5376, Share the Savings with Seniors Act. Issues related to 340B reform; H.R.8574, To amend the Public Health Service Act to reform the 340B drug pricing program, and for other purposes. Issues related to the Ensuring Pathways to Innovative Cures (EPIC) Act, H.R.7174. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-16T07:52:10-04:00
3193474 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION c4e2514f-b359-4f36-b722-bcded121e831 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2024 second_quarter PHA OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. Proposed rule for Nonprescription Drug Product with an Additional Condition for Nonprescription Use H.R. 2964/S. 1350 - The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act FDA Nonprescription Drugs Advisory Committee Meeting on Phenylephrine Activities related to Over-the-Counter Monograph Drug User Fee Drug Enforcement Administration Pseudoephedrine quotas Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 163498   0 0 2024-07-16T10:17:14-04:00
3193513 CARD & ASSOCIATES, LLC 641d7899-4fcc-4215-8232-650bb01041cd Q2 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2024 second_quarter PHA Monitor legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2025 Appropriations Support access to telehealth Monitor and engage on EU digital regulatory policies Monitor international trade issues HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-16T10:27:10-04:00
3193527 BUCHANAN INGERSOLL & ROONEY PC 5f842373-a0c3-46f9-84fe-5213d2e9f3cf Q2 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2024 second_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-16T10:31:18-04:00
3193767 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 5d2731d9-e044-4c3a-a35c-51a773a232ce Q2 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 28264 NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) 2024 second_quarter PHA Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. H.R.7383/S.1214: RARE Act. Inflation Reduction Act Implementation. H.R.4408/S.1906: Promising Pathway Act (PPA). Lab-developed tests (LDTs) and genetic testing access. PRV Reauthorization. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2024-07-16T11:20:31-04:00
3193911 AARP 59253fd4-ef11-4ec2-911f-55836450818c Q2 AARP 1694 AARP 2024 second_quarter PHA No bill number. Discussed out-of-pocket caps for prescription drugs. No bill number. Discussed pharmacy benefit manager reforms. H.R. 4818, the Treat and Reduce Obesity Act. No bill number. Discussed medication safety at home. No bill number. Discussed Medicare drug price negotiation program. No bill number. Discussed Medicare Prescription Payment Plan. S.79, the Interagency Patent Coordination and Improvement Act of 2023. S.142, the Preserve Access to Affordable Generics and Biosimilars Act of 2023. S.148, the Stop STALLING Act. S.150, the Affordable Prescriptions for Patients Act of 2023. S.113, the Prescription Pricing for the People Act of 2023. H.R. 5539/ S. 3131, Optimizing Research Progress Hope and New Cures Act. H.R. 5547/ S. 476, Maintaining Investments in New Innovation Act. H.R. 3549/ S. 1703, the PACE Part D Choice Act of 2023. No bill number. Discussed generic prescription drug shortages. S.2220/ H.R. 4370, the PREVAIL Act. No bill number. Discussed US Patent and Trade Office proposed rule. H.R. 8848, Affordable and Safe Prescription Drug Importation Act of 2024. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   5170000 0 0 2024-07-16T12:11:35-04:00
3194021 SHIONOGI INC. 0dd54bcf-a2d9-4ab4-9353-ff2d5c6b83ec Q2 SHIONOGI INC. 401107081 SHIONOGI INC. 2024 second_quarter PHA Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization; PASTEUR Act (H.R. 2940, S. 1355) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2024-07-16T12:48:24-04:00
3194067 INDEPENDENT PHARMACY COOPERATIVE 3dfa1e4c-d705-4acb-b4f9-d525ab74f15c Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2024 second_quarter PHA IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transparency in Medicaid Act (S. 1038) IPC supports The Modernizing and Ensuring PBM Accountability Act (S 2973) IPC supports Pharmacy and Medically Underserved Areas Enhancement Act (S 1491) IPC supports Protecting Patients Access to Pharmacy Act (S. 2052) IPC supports The Health Care Price Transparency Act (H.R. 4822) IPC supports Lower Cost, More Transparency Act (LCMT) (H.R. 5378) IPC supports Protecting Patients Against PBM Abuses Act (H.R. 2880) IPC Transparency and Fairness for Pharmacies Act (H.R. 5393) IPC supports Senate Bi-Partisan Working Group for 340B Reform - RFI response. IPC Supports FDA - Development of Small Dispensers Assessment Under the Drug Supply Chain Security Act; Request for Comments (FDA-2023-N-3103) IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC opposes S. 1339 Pharmacy Benefits Reform Act - because it may preempt state PBM laws relating to ERISA. IPC supports S. 1491 Pharmacy and Medically Underserved Areas Enhancement Act IPC supports S. 127 Pharmacy Benefit Manager Transparency Act IPC supports (H.R. 1770/S. 2477) The Equitable Community Access to Pharmacists Services Act IPC supports FDA delay of DSCSA enhanced data compliance-request for comments CMS Implementation of PY 2024 Medicare Part D drug rule-comments CMS Implementation of drug provisions of the IRA 2022-comments Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2024-07-16T13:11:49-04:00
3194110 POLSINELLI PC bd9b491e-946a-4cd5-9687-bbd667a06d18 Q2 POLSINELLI PC 314911 RESQ PHARMA 2024 second_quarter PHA FDA Regulatory Issues HOUSE OF REPRESENTATIVES 40000   0 0 2024-07-16T13:28:59-04:00
3194722 BURRELL INTERNATIONAL GROUP LLC 548845d0-bece-4e1a-9dc7-4c128e045d0e Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2024 second_quarter PHA FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-16T16:12:51-04:00
3194792 BURRELL INTERNATIONAL GROUP LLC b088f369-911e-4fc6-ac2e-ce76ea191684 Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2024 second_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products; FY25 Defense Appropriation for broad-spectrum antivirals, FY25 LHHS for long covid and cocaine overdose funding HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-07-16T16:30:38-04:00
3195139 CORNERSTONE GOVERNMENT AFFAIRS, INC. 0476aa5c-2cd4-401e-b956-fa26c0589c8b Q2 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 MICHIGAN HEALTH & HOSPITAL ASSOCIATION 2024 second_quarter PHA Cybersecurity; Medicare outpatient reimbursement; H.R. 5378, Lower Cost, More Transparency Act; Medicaid coverage and Medicaid supplemental payments; health care workforce issues; Rural Emergency Hospital designation; cancer drug shortages; Centers for Medicare & Medicaid Services Minimum Staffing Standards for Long-Term Care Facilities proposed rule; and Medicaid Managed Care State Directed Payments. Engaged with Michigan congressional delegation offices. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-16T21:35:33-04:00
3195177 FORBES-TATE 2a428d81-3666-407f-a44e-fec4536b1dfc Q2 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2024 second_quarter PHA Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency; Issues related to S. 127 - Pharmacy Benefit Manager Transparency Act of 2023; Issues related to S. 1339 - Pharmacy Benefit Manager Reform Act; Issues related to H.R. 3561 - PATIENT Act of 2023; Issues related to S. 2973 - Modernizing and Ensuring PBM Accountability Act; Issues related to H.R. 5378 - the Lower Costs, More Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-07-16T22:49:10-04:00
3195227 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 8001cf17-2591-417a-951d-eb310e253c74 Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2024 second_quarter PHA Opioid Abuse - General issues related to opioid abuse and access to medication assisted treatment HR 1770/S. 2477 - Equitable Community Access to Pharmacist Services Act Implementation of Public Law 113-54 (DSCSA) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   518503 0 0 2024-07-17T08:19:43-04:00
3195369 RUBICON ADVISORS, LLC e4eb1d9c-996b-4316-ab66-b643d79e561b Q2 RUBICON ADVISORS, LLC 315091 ASCENDIS PHARMA, INC. 2024 second_quarter PHA Food and Drug Administration, Orphan Drugs Food & Drug Administration (FDA) 60000   0 0 2024-07-17T09:58:18-04:00
3195383 RUBICON ADVISORS, LLC dc8fe36b-7547-4007-8b68-09eafe94f8be Q2 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2024 second_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 60000   0 0 2024-07-17T10:00:16-04:00
3195385 RUBICON ADVISORS, LLC 943f7490-b278-4bd4-bf51-7a7f1bb03407 Q2 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2024 second_quarter PHA Prescription User Fee, Biomedical Advance Research and Development Authority (BARDA) HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS) 75000   0 0 2024-07-17T10:01:25-04:00
3195388 RUBICON ADVISORS, LLC 22a4f93e-2e92-4772-b78f-32430987e529 2T RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2024 second_quarter PHA Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 35000   0 1 2024-07-17T10:03:20-04:00
3195691 NELSON MULLINS RILEY & SCARBOROUGH d6175d3d-194d-4b5a-8ddd-95593da3b94f Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2024 second_quarter PHA 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-17T11:50:24-04:00
3195707 NELSON MULLINS RILEY & SCARBOROUGH 5d2e4393-dd90-45ca-b34c-30fe52130f00 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 TIDELANDS HEALTH 2024 second_quarter PHA Issues related to the 340B Drug Pricing Program SENATE 40000   0 0 2024-07-17T11:52:47-04:00
3195768 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 3a8218eb-787f-4f33-bc96-8d29fe1e5ccf Q2 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 28526 NATIONAL RURAL LETTER CARRIERS' ASSOCIATION 2024 second_quarter PHA H.R. 6283,"DRUG Act"- legislation that impacts Pharmacy Benefit Managers (PBMs), it could have the unintended consequences of reducing mail volume and increasing the costs/premiums of employer sponsored health programs. The NRLCA has not taken a position on this legislation. S. 1542, "DRUG Act"- Senate companion bill to H.R. 6283, the NRLCA has not taken a position on this bill. HOUSE OF REPRESENTATIVES,SENATE   125000 0 0 2024-07-17T12:06:09-04:00
3195926 ARNOLD & PORTER KAYE SCHOLER LLP 80f83d7a-ba26-4ddf-8b7b-1603e3370a53 Q2 ARNOLD & PORTER KAYE SCHOLER LLP 4301 NOVO NORDISK, INC. 2024 second_quarter PHA Issues related to pharmacy benefit managers and the 340B Program. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2024-07-17T12:43:50-04:00
3195988 BL PARTNERS GROUP, LLC c48a2ead-8b7d-4b19-8967-124bab1ef672 Q2 BL PARTNERS GROUP, LLC 401105341 ALBERTSONS COMPANIES, INC. 2024 second_quarter PHA Issues related to Anti-Trust, Food and Drug Regulation, Supply Chain, Farm to Market Programs, SNAP Programs and Pharmacy benefit Managers - no specific legislation. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-17T13:06:02-04:00
3196262 PRINTING UNITED ALLIANCE 74832e7e-c54c-46e8-bf80-c965428fd5d8 Q2 PRINTING UNITED ALLIANCE 401105682 PRINTING UNITED ALLIANCE 2024 second_quarter PHA Retention of FDA regulations mandating use of pharmaceutical information and prescriber data on paper. Support of H.R. 1173 (118th Congress): Patients Right to Know Their Medication Act. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2024-07-17T13:58:42-04:00
3196492 BURRELL INTERNATIONAL GROUP LLC 5cfcc5eb-c63f-4e4b-9427-5f232b97cad8 2A BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2024 second_quarter PHA FY25 Appropriations and policy for the Strategic National Stockpile, BARDA, and Industrial Base Management Supply Chain, Pandemic and All Hazards Preparedness Act (PAHPA), PASTEUR Act and MCM Development funding; AMR issues. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-17T14:56:06-04:00
3196526 WEST FRONT STRATEGIES LLC 3d6661b5-a616-46cb-8a6d-a6a0764b796e 2T WEST FRONT STRATEGIES LLC 401103493 BLINK HEALTH INC. 2024 second_quarter PHA Monitor issues related to competition in pharmacy. HOUSE OF REPRESENTATIVES,SENATE 20000   0 1 2024-07-17T15:01:20-04:00
3197138 BROWNSTEIN HYATT FARBER SCHRECK, LLP 5a6bac2f-a59a-429e-9e2e-b862f7176bd1 Q2 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 LILLY USA, LLC 2024 second_quarter PHA Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act   90000   0 0 2024-07-17T18:08:02-04:00
3197790 POLARIS GOVERNMENT RELATIONS, LLC 23881714-c5d8-48ed-9c8c-dfecaef8fe91 Q2 POLARIS GOVERNMENT RELATIONS, LLC 307730 CIGNA CORPORATION 2024 second_quarter PHA Drug pricing and issues facing the pharmacy benefit manager industry generally HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2024-07-18T09:39:16-04:00
3197861 MEHLMAN CONSULTING, INC. c9457a43-17a3-4efe-84b5-8b5a5b950ed9 Q2 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2024 second_quarter PHA Prescription drug pricing issues. S. 2305 - Biosimilar Red Tape Elimination Act. S. 148 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 - Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 - Increasing Transparency in Generic Drug Applications Act. S. 1214 - Retaining Access and Restoring Exclusivity (RARE) Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-18T09:58:12-04:00
3197910 MEHLMAN CONSULTING, INC. fc2628d4-246a-4a57-9710-7799c7136691 Q2 MEHLMAN CONSULTING, INC. 284950 HUMANA 2024 second_quarter PHA Prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-07-18T10:04:49-04:00
3198222 DA VINCI GROUP 438f8637-7ba8-4eaf-a2ce-207f3c14e245 Q2 DA VINCI GROUP 11548 BOESEN & SNOW, LLC 2024 second_quarter PHA Health Care Issues and pharmaceutical-related issues, generally; No Specific legislation during this period. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-07-18T10:50:11-04:00
3198266 UNIVERSITY OF IOWA ac1ebc26-865b-41a9-b177-9d715982b55c Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2024 second_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2024-07-18T10:53:13-04:00
3198314 1607 STRATEGIES, LLC 5794acff-4a41-40eb-9878-963605974101 Q2 1607 STRATEGIES, LLC 401105461 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION 2024 second_quarter PHA S. 2793, Modernizing and Ensuring PBM Accountability Act, all provisions. H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act, all provisions. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-18T11:01:21-04:00
3198547 340B HEALTH 3f52596c-2f77-4d73-adef-8db0ec51ed69 Q2 340B HEALTH 316434 340B HEALTH 2024 second_quarter PHA The 340B Drug Pricing Program; H.R. 2534, The Protect 340B Act; FY24 and FY25 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bills. HR 3290,to amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program. H.R.3561 - PATIENT Act of 2023, The Stop Drug Shortages Act (Draft legislation- House), H.R. 5378: Lower Costs, More Transparency Act, S. 1182: 340B Reporting and Accountability Act; S.1133: 340B Accountability Act of 2023,S.1038: Drug Price Transparency in Medicaid Act of 2023,H.R.1613: Drug Price Transparency in Medicaid Act of 2023,H.R.198: Drug Pricing Transparency and Accountability Act; S. 2973: Modernizing and Ensuring PBM Accountability Act, Draft Senate legislation the SUSTAIN 340B Act, HR 7635, the 340B PATIENTS Act.H.R. 8574, 340B ACCESS Act Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   315115 0 0 2024-07-18T11:43:56-04:00
3198573 PANNONE LOPES DEVEREAUX & O'GARA LLC 37e8284c-1bed-4022-8d63-2695d90a0781 Q2 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2024 second_quarter PHA Prescription drug pricing.   9000   0 0 2024-07-18T11:53:47-04:00
3198763 HB STRATEGIES efefc30d-aa6c-491f-80f7-83091f8b20e9 Q2 HB STRATEGIES 401104718 BAYER U.S. LLC 2024 second_quarter PHA Provide lobbying support of key issues and track relevant federal policy developments that could impact the pharmaceutical, healthcare and agricultural industries generally and Bayer specifically. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-18T12:30:54-04:00
3199213 ARENTFOX SCHIFF LLP 8c3f311f-64c3-4996-9a19-380e03256048 Q2 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2024 second_quarter PHA Prescription drug pricing generally Pharmacy Benefit Manager (PBM) reform generally S. 2973 (Modernizing and Ensuring PBM Accountability Act), all provisions S. 1339 (Pharmacy Benefit Manager Reform Act), regarding Pharmacy Benefit Manager (PBM) reform S. 3430 (Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023), regarding Pharmacy Benefit Manager (PBM) reform H.R. 5378 (Lower Costs, More Transparency Act), regarding Pharmacy Benefit Manager (PBM) reform H.R. 6283 (DRUG Act), regarding Pharmacy Benefit Manager (PBM) reform HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2024-07-18T13:37:55-04:00
3199233 ELI LILLY AND COMPANY be29ae3b-fbe7-44cc-bbce-e98250f1f9a5 Q2 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2024 second_quarter PHA Hospital discounts; 340B program HOUSE OF REPRESENTATIVES,SENATE   2465000 0 0 2024-07-18T13:40:10-04:00
3199389 FARRAGUT PARTNERS LLP e9e9849b-e8d1-4748-a2de-c8a1f7722be4 Q2 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2024 second_quarter PHA Issues related to pharmacy benefit managers. TACT Act HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2024-07-18T13:56:42-04:00
3199436 FARRAGUT PARTNERS LLP 07cb3e52-7040-47c1-8940-e3a172a24771 Q2 FARRAGUT PARTNERS LLP 401103938 ONEONCOLOGY INC. 2024 second_quarter PHA Issues related to pharmacy benefit managers. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-18T14:02:34-04:00
3199660 CAPITOL COUNSEL LLC 05f85f4b-f9bc-4358-9994-0c8d665fb0aa Q2 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2024 second_quarter PHA Issues regarding the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-18T14:38:17-04:00
3199694 MARSHALL & POPP, LLC b4d496a9-389a-4854-a9a7-75b1f8850d12 Q2 MARSHALL & POPP, LLC 401105121 ABBVIE INC. 2024 second_quarter PHA Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2024-07-18T14:42:08-04:00
3200202 THE CONSILIO GROUP 839d5f4c-2669-4c16-a1fb-70d8ef5780af Q2 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2024 second_quarter PHA Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 36000   0 0 2024-07-18T15:30:51-04:00
3200437 HANCE SCARBOROUGH d7290961-f9cb-4cfd-8112-156aa06cccb7 Q2 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2024 second_quarter PHA Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-18T15:53:47-04:00
3200457 HANCE SCARBOROUGH b220f3f5-0831-427f-910e-fd6267185d9c 2A HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2024 second_quarter PHA Issues related to the regulation of pharmacy compounding. Issues related to preserving patient access to compounded medications. Fiscal Year 2025 Appropriations HR167, the Patient Access to Urgent Use Compounded Medication Act HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2024-07-18T15:56:57-04:00
3200721 WHITMER & WORRALL, LLC 5d457f88-d852-40d0-b0f8-e72e74c449cc Q2 WHITMER & WORRALL, LLC 292892 CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) 2024 second_quarter PHA Issues related to prescription drug pricing. S. 2305 Biosimilar Red Tape Elimination Act. S. 148 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. S. 1067 Ensuring Timely Access to Generics Act. S. 775/H.R. 3839 Increasing Transparency in Generic Drug Applications Act. S. 1214 Retaining Access and Restoring Exclusivity (RARE) Act. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2024-07-18T16:33:09-04:00
3200831 TRUSYNERGY 34a06cb7-ee48-4a6b-9f84-7a59a2e86f40 Q2 TRUSYNERGY 401107715 BURRELL INTERNATIONAL GROUP LLC (ON BEHALF OF SHIONOGI INC.) 2024 second_quarter PHA Funding for the SNS, BARDA, and IBMSC; promoting safer and more effective treatments in the stockpile; promoting onshoring and domestic manufacturing of medicines and their components; prioritizing investments in more effective treatments to combat AMR; PASTEUR Act; reauthorization of the Pandemic and All Hazards Preparedness Act; funding and incentives for MCM development; AMR issues; development of infectious disease and AMR treatments; FY 25 LHHS appropriations; MCM PRV; SUPER BUGS Act HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2024-07-18T16:44:46-04:00
3200877 SUSAN B ANTHONY LIST 1e68aa5d-9cbf-433d-8879-728905aba7d4 Q2 SUSAN B ANTHONY LIST 400935704 SUSAN B ANTHONY LIST 2024 second_quarter PHA Shield laws; H.R. 427, S. 95 Support and Value Expectant Moms and Babies Act; Chemical abortion; Support and Value Expectant Moms and Babies Act HOUSE OF REPRESENTATIVES,SENATE   300000 0 0 2024-07-18T16:47:23-04:00
3201006 MEHLMAN CONSULTING, INC. 07a0253f-f196-44c9-817b-c84d839f7466 Q2 MEHLMAN CONSULTING, INC. 284950 WEDGEWOOD PHARMACY LLC 2024 second_quarter PHA Issues related to animal drug compounding. Issues related to FDA's CVM GFI #256 - Compounding Animal Drugs from Bulk Substances. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2024-07-18T16:58:39-04:00
3201112 HIGHMARK, INC. 3606104e-7113-4b28-9380-5d42f0e2f9b0 Q2 HIGHMARK, INC. 18238 HIGHMARK INC 2024 second_quarter PHA Insulin Copay Caps, Drug Pricing, Pharmacy Benefit Manager (PBM) Reform, Generic Drug Manufacturing Senate Finance Committee PBM Reform Framework H.R. 5378 - The Lower Costs, More Transparency Act - A bill to require health care providers and insurers to disclose certain information about health care costs. It also establishes requirements for certain payment methodologies under Medicare and Medicaid and extends several public health programs. H.R. 1488/S. 954 - The Affordable Insulin Now Act -- A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. S. 127. - The Pharmacy Benefit Manager Transparency Act - This bill generally prohibits pharmacy benefit managers (PBMs) from engaging in certain practices when managing the prescription drug benefits under a health insurance plan, including charging the plan a different amount than the PBM reimburses the pharmacy. S.1339 - The Pharmacy Benefit Manager Reform Act - A bill to provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. H.R.2679 - The Pharmacy Benefits Manager Accountability Act - A bill to amend the Public Health Service Act, the Employee Retirement Income Security Act, and the Internal Revenue Code of 1984 to increase oversight of pharmacy benefits manager services, and for other purposes. H.R. 3561 - PATIENT Act of 2023 - This bill expands hospital price transparency requirements and establishes additional reporting requirements with respect to prescription drugs and pharmacy benefit managers (PBMs). H.R. 2630/S. 652 - The Safe Step Act -- This bill requires a group health plan to establish an exception to medication step-therapy protocol in specified cases. A medication step-therapy protocol establishes a specific sequence in which prescription drugs are covered by a … HOUSE OF REPRESENTATIVES,SENATE   170000 0 0 2024-07-18T17:05:02-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 3382.415ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API